Grace Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Grace Therapeutics stock have an average target of 6.00, with a low estimate of 4.00 and a high estimate of 8.00. The average target predicts an increase of 152.10% from the current stock price of 2.38.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$4.00	$6.00	$8.00	$8.00
Change	+68.07%	+152.10%	+236.13%	+236.13%

Analyst Ratings

The average analyst rating for Grace Therapeutics stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jun '25	Aug '25	Nov '25	Feb '26	Apr '26	Jun '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Chase Knickerbocker Craig-Hallum	Craig-Hallum	Buy Reiterates $4	Buy	Reiterates	$4	+68.07%	Jun 22, 2026
Stacy Ku TD Cowen	TD Cowen	Buy Reiterates $12 → $8	Buy	Reiterates	$12 → $8	+236.13%	Apr 23, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

5.52M

EPS This Year

-0.52

from -0.46

EPS Next Year

-0.55

from -0.52

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028
Period Ending	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027	Mar 31, 2028
Revenue	-	-	-	-	-	-	5.52M
Revenue Growth	-	-	-	-	-	-	-
EPS	-1.60	-5.71	-1.35	-0.79	-0.47	-0.52	-0.55
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	2	2

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2027	2028
High	n/a	9.6M
Avg	n/a	5.5M
Low	n/a	1.4M

Revenue Growth

Revenue Growth	2028	2029
High	-	685.9%
Avg	-	685.9%
Low	-	685.9%

EPS Forecast

EPS	2027	2028
High	-0.52	-0.48
Avg	-0.52	-0.55
Low	-0.52	-0.61

EPS Growth

EPS Growth	2027	2028
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.